Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.

ABSTRACT:

Objective

To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators.

Methods

A post hoc assessment of cardiovascular safety in 14,611 patients was performed by pooling data from 25 double-blind studies, which randomised patients at baseline to sitagliptin 100 mg/day or a non-sitagliptin comparator (i.e., non-exposed). Included studies were limited to those at least 12 weeks in duration (range: 12 to 104 weeks). Patient-level data were used in this analysis of major adverse cardiovascular events (MACE) including ischaemic events and cardiovascular deaths. Analyses were performed in three cohorts: the entire 25-study cohort, the cohort from placebo-controlled portions of stu

SUBMITTER: Engel SS 

PROVIDER: S-EPMC3585887 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature